clinical trial · NCT04924608
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
AstraZeneca·phase3·active not recruiting·n = 145
Neurofibromatosis 1Plexiform Neurofibroma (PN)SelumetinibPlacebo
brief summary
A global study to demonstrate the effectiveness of selumetinib in participants with NF1 who have symptomatic, inoperable plexiform neurofibromas.
started
Nov 19, 2021
primary completion
Aug 5, 2024
completion
Feb 15, 2029
last updated
Mar 23, 2026
detailed description
This is a randomized, double-blind, placebo-controlled, 2 arm multicentre, global Phase III study to assess the efficacy and safety of selumetinib compared with placebo in adult participants with NF1 who have symptomatic, inoperable PN.
official title
A Phase III, Multicentre, International Study With a Parallel, Randomised, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol